1
|
Oliaei SS, Habibi D, Heydari S, Karamian R, Ghasemian Sorboni S. Unexpected synthesis of 4-(4,5-dihydro-1H-imidazol-2-ylsulfanyl)butyl-H-sulfite as a catalyst for the synthesis of pyrazolophthalazines. Mol Divers 2023; 27:2453-2464. [PMID: 36400897 DOI: 10.1007/s11030-022-10563-w] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/20/2022] [Accepted: 10/29/2022] [Indexed: 11/19/2022]
Abstract
Several attempts for preparation of 4,4'-(2-thioxoimidazolidine-1,3-diyl)bis(butane-1-sulfonic acid) were not successful despite taking 2 mmol of 1,4-butane sultone in reaction with 1 mmol of imidazolidine-2-thione. Instead, 4-(4,5-dihydro-1H-imidazol-2-ylsulfanyl)butyl hydrogen sulfite (DISBHS) was prepared unexpectedly, characterized and used for the synthesis of diverse pyrazolophthalazines from the one-pot three component condensation reaction of phthalhydrazide, malononitrile and aldehydes under mild conditions.
Collapse
Affiliation(s)
- Seyyed Sajjad Oliaei
- Department of Organic Chemistry, Faculty of Chemistry, Bu-Ali Sina University, Hamedan, 6517838683, Iran
| | - Davood Habibi
- Department of Organic Chemistry, Faculty of Chemistry, Bu-Ali Sina University, Hamedan, 6517838683, Iran.
| | - Somayyeh Heydari
- Social Determinants of Health Research Center, Saveh University of Medical Sciences, Saveh, Iran
| | - Roya Karamian
- Department of Biology, College of Science, Bu-Ali Sina University, Hamedan, 6517838683, Iran
| | | |
Collapse
|
2
|
Smith CR, Aranda R, Bobinski TP, Briere DM, Burns AC, Christensen JG, Clarine J, Engstrom LD, Gunn RJ, Ivetac A, Jean-Baptiste R, Ketcham JM, Kobayashi M, Kuehler J, Kulyk S, Lawson JD, Moya K, Olson P, Rahbaek L, Thomas NC, Wang X, Waters LM, Marx MA. Fragment-Based Discovery of MRTX1719, a Synthetic Lethal Inhibitor of the PRMT5•MTA Complex for the Treatment of MTAP-Deleted Cancers. J Med Chem 2022; 65:1749-1766. [PMID: 35041419 DOI: 10.1021/acs.jmedchem.1c01900] [Citation(s) in RCA: 47] [Impact Index Per Article: 23.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
Abstract
The PRMT5•MTA complex has recently emerged as a new synthetically lethal drug target for the treatment of MTAP-deleted cancers. Here, we report the discovery of development candidate MRTX1719. MRTX1719 is a potent and selective binder to the PRMT5•MTA complex and selectively inhibits PRMT5 activity in MTAP-deleted cells compared to MTAP-wild-type cells. Daily oral administration of MRTX1719 to tumor xenograft-bearing mice demonstrated dose-dependent inhibition of PRMT5-dependent symmetric dimethylarginine protein modification in MTAP-deleted tumors that correlated with antitumor activity. A 4-(aminomethyl)phthalazin-1(2H)-one hit was identified through a fragment-based screen, followed by X-ray crystallography, to confirm binding to the PRMT5•MTA complex. Fragment growth supported by structural insights from X-ray crystallography coupled with optimization of pharmacokinetic properties aided the discovery of development candidate MRTX1719.
Collapse
Affiliation(s)
| | - Ruth Aranda
- Mirati Therapeutics, San Diego, California 92121, United States
| | | | - David M Briere
- Mirati Therapeutics, San Diego, California 92121, United States
| | - Aaron C Burns
- Mirati Therapeutics, San Diego, California 92121, United States
| | | | - Jeffery Clarine
- Mirati Therapeutics, San Diego, California 92121, United States
| | - Lars D Engstrom
- Mirati Therapeutics, San Diego, California 92121, United States
| | - Robin J Gunn
- Mirati Therapeutics, San Diego, California 92121, United States
| | - Anthony Ivetac
- Mirati Therapeutics, San Diego, California 92121, United States
| | | | - John M Ketcham
- Mirati Therapeutics, San Diego, California 92121, United States
| | | | - Jon Kuehler
- Mirati Therapeutics, San Diego, California 92121, United States
| | - Svitlana Kulyk
- Mirati Therapeutics, San Diego, California 92121, United States
| | - J David Lawson
- Mirati Therapeutics, San Diego, California 92121, United States
| | - Krystal Moya
- Mirati Therapeutics, San Diego, California 92121, United States
| | - Peter Olson
- Mirati Therapeutics, San Diego, California 92121, United States
| | - Lisa Rahbaek
- Mirati Therapeutics, San Diego, California 92121, United States
| | - Nicole C Thomas
- Mirati Therapeutics, San Diego, California 92121, United States
| | - Xiaolun Wang
- Mirati Therapeutics, San Diego, California 92121, United States
| | - Laura M Waters
- Mirati Therapeutics, San Diego, California 92121, United States
| | - Matthew A Marx
- Mirati Therapeutics, San Diego, California 92121, United States
| |
Collapse
|
3
|
Guibbal F, Hopkins SL, Pacelli A, Isenegger PG, Mosley M, Torres JB, Dias GM, Mahaut D, Hueting R, Gouverneur V, Cornelissen B. [ 18F]AZD2461, an Insight on Difference in PARP Binding Profiles for DNA Damage Response PET Imaging. Mol Imaging Biol 2020; 22:1226-1234. [PMID: 32342268 PMCID: PMC7497465 DOI: 10.1007/s11307-020-01497-6] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Abstract
BACKGROUND Poly (ADP-ribose) polymerase (PARP) inhibitors are extensively studied and used as anti-cancer drugs, as single agents or in combination with other therapies. Most radiotracers developed to date have been chosen on the basis of strong PARP1-3 affinity. Herein, we propose to study AZD2461, a PARP inhibitor with lower affinity towards PARP3, and to investigate its potential for PARP targeting in vivo. METHODS Using the Cu-mediated 18F-fluorodeboronation of a carefully designed radiolabelling precursor, we accessed the 18F-labelled isotopologue of the PARP inhibitor AZD2461. Cell uptake of [18F]AZD2461 in vitro was assessed in a range of pancreatic cell lines (PSN-1, PANC-1, CFPAC-1 and AsPC-1) to assess PARP expression and in vivo in xenograft-bearing mice. Blocking experiments were performed with both olaparib and AZD2461. RESULTS [18F]AZD2461 was efficiently radiolabelled via both manual and automated procedures (9 % ± 3 % and 3 % ± 1 % activity yields non-decay corrected). [18F]AZD2461 was taken up in vivo in PARP1-expressing tumours, and the highest uptake was observed for PSN-1 cells (7.34 ± 1.16 %ID/g). In vitro blocking experiments showed a lesser ability of olaparib to reduce [18F]AZD2461 binding, indicating a difference in selectivity between olaparib and AZD2461. CONCLUSION Taken together, we show the importance of screening the PARP selectivity profile of radiolabelled PARP inhibitors for use as PET imaging agents.
Collapse
Affiliation(s)
- Florian Guibbal
- Department of Oncology, CRUK/MRC Oxford Institute for Radiation Oncology, University of Oxford, Old Road Campus Research Building , Off Roosevelt Drive, Oxford, OX3 7LJ UK
- Department of Chemistry, Chemistry Research Laboratory, University of Oxford, 12 Mansfield Road, Oxford, OX1 3TA UK
| | - Samantha L. Hopkins
- Department of Oncology, CRUK/MRC Oxford Institute for Radiation Oncology, University of Oxford, Old Road Campus Research Building , Off Roosevelt Drive, Oxford, OX3 7LJ UK
| | - Anna Pacelli
- Department of Oncology, CRUK/MRC Oxford Institute for Radiation Oncology, University of Oxford, Old Road Campus Research Building , Off Roosevelt Drive, Oxford, OX3 7LJ UK
| | - Patrick G. Isenegger
- Department of Chemistry, Chemistry Research Laboratory, University of Oxford, 12 Mansfield Road, Oxford, OX1 3TA UK
| | - Michael Mosley
- Department of Oncology, CRUK/MRC Oxford Institute for Radiation Oncology, University of Oxford, Old Road Campus Research Building , Off Roosevelt Drive, Oxford, OX3 7LJ UK
| | - Julia Baguña Torres
- Department of Oncology, CRUK/MRC Oxford Institute for Radiation Oncology, University of Oxford, Old Road Campus Research Building , Off Roosevelt Drive, Oxford, OX3 7LJ UK
| | - Gemma M. Dias
- Department of Oncology, CRUK/MRC Oxford Institute for Radiation Oncology, University of Oxford, Old Road Campus Research Building , Off Roosevelt Drive, Oxford, OX3 7LJ UK
| | - Damien Mahaut
- Department of Chemistry, Chemistry Research Laboratory, University of Oxford, 12 Mansfield Road, Oxford, OX1 3TA UK
| | - Rebekka Hueting
- Department of Oncology, CRUK/MRC Oxford Institute for Radiation Oncology, University of Oxford, Old Road Campus Research Building , Off Roosevelt Drive, Oxford, OX3 7LJ UK
| | - Véronique Gouverneur
- Department of Chemistry, Chemistry Research Laboratory, University of Oxford, 12 Mansfield Road, Oxford, OX1 3TA UK
| | - Bart Cornelissen
- Department of Oncology, CRUK/MRC Oxford Institute for Radiation Oncology, University of Oxford, Old Road Campus Research Building , Off Roosevelt Drive, Oxford, OX3 7LJ UK
| |
Collapse
|
4
|
Guibbal F, Isenegger PG, Wilson TC, Pacelli A, Mahaut D, Sap JBI, Taylor NJ, Verhoog S, Preshlock S, Hueting R, Cornelissen B, Gouverneur V. Manual and automated Cu-mediated radiosynthesis of the PARP inhibitor [ 18F]olaparib. Nat Protoc 2020; 15:1525-1541. [PMID: 32111986 DOI: 10.1038/s41596-020-0295-7] [Citation(s) in RCA: 30] [Impact Index Per Article: 7.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/14/2019] [Accepted: 01/06/2020] [Indexed: 02/04/2023]
Abstract
Positron emission tomography (PET) is a diagnostic nuclear imaging modality that relies on automated protocols to prepare agents labeled with a positron-emitting radionuclide (e.g., 18F). In recent years, new reactions have appeared for the 18F-labeling of agents that are difficult to access by applying traditional radiochemistry, for example those requiring 18F incorporation into unactivated (hetero)arenes. However, automation of these new methods for translation to the clinic has progressed slowly because extensive modification of manual protocols is typically required when implementing novel 18F-labeling methodologies within automated modules. Here, we describe the workflow that led to the automated radiosynthesis of the poly(ADP-ribose) polymerase (PARP) inhibitor [18F]olaparib. First, we established a robust manual protocol to prepare [18F]olaparib from the protected N-[2-(trimethylsilyl)ethoxy]methyl (SEM) arylboronate ester precursor in a 17% ± 5% (n = 15; synthesis time, 135 min) non-decay-corrected (NDC) activity yield, with molar activity (Am) up to 34.6 GBq/µmol. Automation of the process, consisting of copper-mediated 18F-fluorodeboronation followed by deprotection, was achieved on an Eckert & Ziegler Modular-Lab radiosynthesis platform, affording [18F]olaparib in a 6% ± 5% (n = 3; synthesis time, 120 min) NDC activity yield with Am up to 319 GBq/µmol.
Collapse
Affiliation(s)
- Florian Guibbal
- Chemistry Research Laboratory, University of Oxford, Oxford, UK
- Radiobiology Research Institute, Department of Oncology, Churchill Hospital, University of Oxford, Headington, UK
| | | | - Thomas C Wilson
- Chemistry Research Laboratory, University of Oxford, Oxford, UK
| | - Anna Pacelli
- Radiobiology Research Institute, Department of Oncology, Churchill Hospital, University of Oxford, Headington, UK
| | - Damien Mahaut
- Chemistry Research Laboratory, University of Oxford, Oxford, UK
| | - Jeroen B I Sap
- Chemistry Research Laboratory, University of Oxford, Oxford, UK
| | | | - Stefan Verhoog
- Chemistry Research Laboratory, University of Oxford, Oxford, UK
| | - Sean Preshlock
- Chemistry Research Laboratory, University of Oxford, Oxford, UK
| | - Rebekka Hueting
- Radiobiology Research Institute, Department of Oncology, Churchill Hospital, University of Oxford, Headington, UK
| | - Bart Cornelissen
- Radiobiology Research Institute, Department of Oncology, Churchill Hospital, University of Oxford, Headington, UK.
| | | |
Collapse
|
5
|
Li J, Xiao D, Liu L, Xie F, Li W, Sun W, Yang X, Zhou X. Design, Synthesis, and In Vitro Evaluation of the Photoactivatable Prodrug of the PARP Inhibitor Talazoparib. Molecules 2020; 25:molecules25020407. [PMID: 31963730 PMCID: PMC7024556 DOI: 10.3390/molecules25020407] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/26/2019] [Revised: 01/16/2020] [Accepted: 01/16/2020] [Indexed: 12/13/2022] Open
Abstract
In this article, we report the design, synthesis, photodynamic properties, and in vitro evaluation of photoactivatable prodrug for the poly (ADP-ribose) polymerase 1 (PARP-1) inhibitor Talazoparib. In order to yield a photoactivatable, inactive prodrug, photoactivatable protecting groups (PPGs) were employed to mask the key pharmacophore of Talazoparib. Our study confirmed the good stability and photolytic effect of prodrugs. A PARP-1 enzyme inhibition assay and PARylation experiment showed that the inhibitory activity of the prodrug was reduced 380 times and more than 658 times, respectively, which proved that the prodrug's expected activity was lost after PPG protection. In BRCA1- and BRCA2-deficient cell lines, the inhibitory activity of the compound was significantly restored after ultraviolet (UV) irradiation. The results indicate that the photoactivatable prodrug strategy is an interesting approach for studying PARP inhibitors. Meanwhile, the described photoactivatable prodrug also provided a new biological tool for the mechanism research of PARP.
Collapse
Affiliation(s)
- Jiaguo Li
- School of Pharmaceutical Sciences, Jilin University, Changchun 130021, China;
- National Engineering Research Center for the Emergency Drug, Beijing Institute of Pharmacology and Toxicology, Beijing 100850, China; (D.X.); (L.L.); (F.X.); (W.L.)
| | - Dian Xiao
- National Engineering Research Center for the Emergency Drug, Beijing Institute of Pharmacology and Toxicology, Beijing 100850, China; (D.X.); (L.L.); (F.X.); (W.L.)
| | - Lianqi Liu
- National Engineering Research Center for the Emergency Drug, Beijing Institute of Pharmacology and Toxicology, Beijing 100850, China; (D.X.); (L.L.); (F.X.); (W.L.)
| | - Fei Xie
- National Engineering Research Center for the Emergency Drug, Beijing Institute of Pharmacology and Toxicology, Beijing 100850, China; (D.X.); (L.L.); (F.X.); (W.L.)
| | - Wei Li
- National Engineering Research Center for the Emergency Drug, Beijing Institute of Pharmacology and Toxicology, Beijing 100850, China; (D.X.); (L.L.); (F.X.); (W.L.)
| | - Wei Sun
- School of Pharmaceutical Sciences, Jilin University, Changchun 130021, China;
- Correspondence: (W.S.); (X.Y.); (X.Z.); Tel.: +86-010-6693-0674 (X.Z.)
| | - Xiaohong Yang
- School of Pharmaceutical Sciences, Jilin University, Changchun 130021, China;
- Correspondence: (W.S.); (X.Y.); (X.Z.); Tel.: +86-010-6693-0674 (X.Z.)
| | - Xinbo Zhou
- National Engineering Research Center for the Emergency Drug, Beijing Institute of Pharmacology and Toxicology, Beijing 100850, China; (D.X.); (L.L.); (F.X.); (W.L.)
- Correspondence: (W.S.); (X.Y.); (X.Z.); Tel.: +86-010-6693-0674 (X.Z.)
| |
Collapse
|
6
|
Popovici L, Amarandi RM, Mangalagiu II, Mangalagiu V, Danac R. Synthesis, molecular modelling and anticancer evaluation of new pyrrolo[1,2-b]pyridazine and pyrrolo[2,1-a]phthalazine derivatives. J Enzyme Inhib Med Chem 2019; 34:230-243. [PMID: 30734610 PMCID: PMC6327994 DOI: 10.1080/14756366.2018.1550085] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/23/2018] [Revised: 11/14/2018] [Accepted: 11/14/2018] [Indexed: 12/02/2022] Open
Abstract
Two new series of heterocyclic derivatives with potential anticancer activity, in which a pyrrolo[1,2-b]pyridazine or a pyrrolo[2,1-a]phthalazine moiety was introduced in place of the 3'-hydroxy-4'-methoxyphenyl ring of phenstatin have been synthesised and their structure-activity relationship (SAR) was studied. Fourteen of the new compounds were evaluated for their in vitro cytotoxic activity by National Cancer Institute (NCI) against 60 human tumour cell lines panel. The best five compounds in terms of in vitro growth inhibition were screened in the second stage five dose-response studies, three of them showing a very good antiproliferative activity with GI50<100 nM on several cell lines including colon, ovarian, renal, prostate, brain and breast cancer, melanoma and leukemia. Docking experiments on the biologically active compounds showed a good compatibility with the colchicine binding site of tubulin.
Collapse
Affiliation(s)
| | | | | | - Violeta Mangalagiu
- CERNESIM Research Centre, Alexandru Ioan Cuza University of Iasi, Iasi, Romania
| | - Ramona Danac
- Faculty of Chemistry, Alexandru Ioan Cuza University of Iasi, Iasi, Romania
| |
Collapse
|
7
|
Reilly SW, Puentes LN, Schmitz A, Hsieh CJ, Weng CC, Hou C, Li S, Kuo YM, Padakanti P, Lee H, Riad AA, Makvandi M, Mach RH. Synthesis and evaluation of an AZD2461 [ 18F]PET probe in non-human primates reveals the PARP-1 inhibitor to be non-blood-brain barrier penetrant. Bioorg Chem 2019; 83:242-249. [PMID: 30390553 PMCID: PMC6378121 DOI: 10.1016/j.bioorg.2018.10.015] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/12/2018] [Revised: 10/08/2018] [Accepted: 10/09/2018] [Indexed: 01/05/2023]
Abstract
Poly(ADP-ribose)polymerase-1 inhibitor (PARPi) AZD2461 was designed to be a weak P-glycoprotein (P-gp) analogue of FDA approved olaparib. With this chemical property in mind, we utilized the AZD2461 ligand architecture to develop a CNS penetrant and PARP-1 selective imaging probe, in order to investigate PARP-1 mediated neuroinflammation and neurodegenerative diseases, such as Alzheimer's and Parkinson's. Our work led to the identification of several high-affinity PARPi, including AZD2461 congener 9e (PARP-1 IC50 = 3.9 ± 1.2 nM), which was further evaluated as a potential 18F-PET brain imaging probe. However, despite the similar molecular scaffolds of 9e and AZD2461, our studies revealed non-appreciable brain-uptake of [18F]9e in non-human primates, suggesting AZD2461 to be non-CNS penetrant.
Collapse
Affiliation(s)
- Sean W Reilly
- Department of Radiology, University of Pennsylvania, Philadelphia, PA 19104, USA
| | - Laura N Puentes
- Department of Systems Pharmacology and Translational Therapeutics, University of Pennsylvania, 421 Curie Boulevard, Philadelphia, PA 19104, USA
| | - Alexander Schmitz
- Department of Radiology, University of Pennsylvania, Philadelphia, PA 19104, USA
| | - Chia-Ju Hsieh
- Department of Radiology, University of Pennsylvania, Philadelphia, PA 19104, USA
| | - Chi-Chang Weng
- Department of Radiology, University of Pennsylvania, Philadelphia, PA 19104, USA
| | - Catherine Hou
- Department of Radiology, University of Pennsylvania, Philadelphia, PA 19104, USA
| | - Shihong Li
- Department of Radiology, University of Pennsylvania, Philadelphia, PA 19104, USA
| | - Yin-Ming Kuo
- Department of Radiology, University of Pennsylvania, Philadelphia, PA 19104, USA
| | - Prashanth Padakanti
- Department of Radiology, University of Pennsylvania, Philadelphia, PA 19104, USA
| | - Hsiaoju Lee
- Department of Radiology, University of Pennsylvania, Philadelphia, PA 19104, USA
| | - Aladdin A Riad
- Department of Radiology, University of Pennsylvania, Philadelphia, PA 19104, USA
| | - Mehran Makvandi
- Department of Radiology, University of Pennsylvania, Philadelphia, PA 19104, USA.
| | - Robert H Mach
- Department of Radiology, University of Pennsylvania, Philadelphia, PA 19104, USA.
| |
Collapse
|
8
|
Yang L, Wang W, Sun Q, Xu F, Niu Y, Wang C, Liang L, Xu P. Development of novel proteasome inhibitors based on phthalazinone scaffold. Bioorg Med Chem Lett 2016; 26:2801-2805. [PMID: 27158142 DOI: 10.1016/j.bmcl.2016.04.067] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/12/2016] [Revised: 04/11/2016] [Accepted: 04/23/2016] [Indexed: 11/18/2022]
Abstract
In this study we designed a series of proteasome inhibitors using pyridazinone as initial scaffold, and extended the structure with rational design by computer aided drug design (CADD). Two different synthetic routes were explored and the biological evaluation of the phthalazinone derivatives was investigated. Most importantly, electron positive triphenylphosphine group was first introduced in the structure of proteasome inhibitors and potent inhibition was achieved. As 6c was the most potent inhibitor of proteasome, we examined the structure-activity relationship (SAR) of 6c analogs.
Collapse
Affiliation(s)
- Lingfei Yang
- Department of Medicinal Chemistry, School of Pharmaceutical Sciences, Peking University Health Science Center, Beijing 100191, China
| | - Wei Wang
- Department of Medicinal Chemistry, School of Pharmaceutical Sciences, Peking University Health Science Center, Beijing 100191, China
| | - Qi Sun
- Department of Medicinal Chemistry, School of Pharmaceutical Sciences, Peking University Health Science Center, Beijing 100191, China
| | - Fengrong Xu
- Department of Medicinal Chemistry, School of Pharmaceutical Sciences, Peking University Health Science Center, Beijing 100191, China
| | - Yan Niu
- Department of Medicinal Chemistry, School of Pharmaceutical Sciences, Peking University Health Science Center, Beijing 100191, China
| | - Chao Wang
- Department of Medicinal Chemistry, School of Pharmaceutical Sciences, Peking University Health Science Center, Beijing 100191, China
| | - Lei Liang
- Department of Medicinal Chemistry, School of Pharmaceutical Sciences, Peking University Health Science Center, Beijing 100191, China.
| | - Ping Xu
- Department of Medicinal Chemistry, School of Pharmaceutical Sciences, Peking University Health Science Center, Beijing 100191, China
| |
Collapse
|
9
|
Muddala NP, Nammalwar B, Selvaraju S, Bourne CR, Henry M, Bunce RA, Berlin KD, Barrow EW, Barrow WW. Evaluation of New Dihydrophthalazine-Appended 2,4-Diaminopyrimidines against Bacillus anthracis: Improved Syntheses Using a New Pincer Complex. Molecules 2015; 20:7222-44. [PMID: 25905602 PMCID: PMC4445145 DOI: 10.3390/molecules20047222] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/20/2015] [Revised: 04/14/2015] [Accepted: 04/15/2015] [Indexed: 02/05/2023] Open
Abstract
The synthesis and evaluation of ten new dihydrophthalazine-appended 2,4-diaminopyrimidines as potential drugs to treat Bacillus anthracis is reported. An improved synthesis utilizing a new pincer catalyst, dichlorobis[1-(dicyclohexylphosphanyl)-piperidine]palladium(II), allows the final Heck coupling to be performed at 90 °C using triethylamine as the base. These milder conditions have been used to achieve improved yields for new and previously reported substrates with functional groups that degrade or react at the normal 140 °C reaction temperature. An analytical protocol for separating the S and R enantiomers of two of the most active compounds is also disclosed. Finally, the X-ray structure for the most active enantiomer of the lead compound, (S)-RAB1, is given.
Collapse
Affiliation(s)
- Nagendra Prasad Muddala
- Department of Chemistry, Oklahoma State University, 107 Physical Sciences, Stillwater, OK 74078, USA.
| | - Baskar Nammalwar
- Department of Chemistry, Oklahoma State University, 107 Physical Sciences, Stillwater, OK 74078, USA.
| | - Subhashini Selvaraju
- Department of Chemistry, Oklahoma State University, 107 Physical Sciences, Stillwater, OK 74078, USA.
| | - Christina R Bourne
- Department of Chemistry and Biochemistry, University of Oklahoma, 101 Stephenson Parkway, Norman, OK 73019, USA.
| | - Mary Henry
- Department of Veterinary Pathobiology, Oklahoma State University, 250 McElroy Hall, Stillwater, OK 74078, USA.
| | - Richard A Bunce
- Department of Chemistry, Oklahoma State University, 107 Physical Sciences, Stillwater, OK 74078, USA.
| | - K Darrell Berlin
- Department of Chemistry, Oklahoma State University, 107 Physical Sciences, Stillwater, OK 74078, USA.
| | - Esther W Barrow
- Department of Veterinary Pathobiology, Oklahoma State University, 250 McElroy Hall, Stillwater, OK 74078, USA.
| | - William W Barrow
- Department of Veterinary Pathobiology, Oklahoma State University, 250 McElroy Hall, Stillwater, OK 74078, USA.
| |
Collapse
|
10
|
Xue DQ, Zhang XY, Wang CJ, Ma LY, Zhu N, He P, Shao KP, Chen PJ, Gu YF, Zhang XS, Wang CF, Ji CH, Zhang QR, Liu HM. Synthesis and anticancer activities of novel 1,2,4-triazolo[3,4-a]phthalazine derivatives. Eur J Med Chem 2014; 85:235-44. [PMID: 25086915 DOI: 10.1016/j.ejmech.2014.07.031] [Citation(s) in RCA: 48] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/08/2014] [Revised: 07/08/2014] [Accepted: 07/09/2014] [Indexed: 11/29/2022]
Affiliation(s)
- Deng-Qi Xue
- New Drug Research & Development Center, School of Pharmaceutical Sciences, Zhengzhou University, No. 100, KeXue DaDao, Zhengzhou 450001, China
| | - Xu-Yao Zhang
- New Drug Research & Development Center, School of Pharmaceutical Sciences, Zhengzhou University, No. 100, KeXue DaDao, Zhengzhou 450001, China
| | - Chao-Jie Wang
- New Drug Research & Development Center, School of Pharmaceutical Sciences, Zhengzhou University, No. 100, KeXue DaDao, Zhengzhou 450001, China
| | - Li-Ying Ma
- New Drug Research & Development Center, School of Pharmaceutical Sciences, Zhengzhou University, No. 100, KeXue DaDao, Zhengzhou 450001, China
| | - Nan Zhu
- New Drug Research & Development Center, School of Pharmaceutical Sciences, Zhengzhou University, No. 100, KeXue DaDao, Zhengzhou 450001, China
| | - Peng He
- New Drug Research & Development Center, School of Pharmaceutical Sciences, Zhengzhou University, No. 100, KeXue DaDao, Zhengzhou 450001, China
| | - Kun-Peng Shao
- New Drug Research & Development Center, School of Pharmaceutical Sciences, Zhengzhou University, No. 100, KeXue DaDao, Zhengzhou 450001, China
| | - Peng-Ju Chen
- New Drug Research & Development Center, School of Pharmaceutical Sciences, Zhengzhou University, No. 100, KeXue DaDao, Zhengzhou 450001, China
| | - Yi-Fei Gu
- New Drug Research & Development Center, School of Pharmaceutical Sciences, Zhengzhou University, No. 100, KeXue DaDao, Zhengzhou 450001, China
| | - Xiao-Song Zhang
- New Drug Research & Development Center, School of Pharmaceutical Sciences, Zhengzhou University, No. 100, KeXue DaDao, Zhengzhou 450001, China
| | - Cai-Feng Wang
- New Drug Research & Development Center, School of Pharmaceutical Sciences, Zhengzhou University, No. 100, KeXue DaDao, Zhengzhou 450001, China
| | - Cong-Hui Ji
- New Drug Research & Development Center, School of Pharmaceutical Sciences, Zhengzhou University, No. 100, KeXue DaDao, Zhengzhou 450001, China
| | - Qiu-Rong Zhang
- New Drug Research & Development Center, School of Pharmaceutical Sciences, Zhengzhou University, No. 100, KeXue DaDao, Zhengzhou 450001, China.
| | - Hong-Min Liu
- New Drug Research & Development Center, School of Pharmaceutical Sciences, Zhengzhou University, No. 100, KeXue DaDao, Zhengzhou 450001, China.
| |
Collapse
|
11
|
Wang YL, Wang QH, Yang HG, Hao BJ, Liang GD, Jiang CG, Cheng MS. [Synthesis and immunosuppressive effects of novel phthalazine ketone derivatives]. Yao Xue Xue Bao 2013; 48:1579-1584. [PMID: 24417085] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/03/2023]
Abstract
A series of phthalazine ketone compounds were synthesized and the structures were confirmed by H NMR and HR-MS spectrum. All target compounds were obtained through 7 steps, including selective reduction, nitration, bromination, ring enlargement, reduction, Knoevenagel and acylated reaction. The compounds were evaluated for their immunosuppressive effects of T-cell proliferation and inhibitory activity of IMPDH type II in vitro, as well as their structure-activity relationship were assessed. Several compounds exhibited strong immunosuppressive properties, especially compounds 7f and 7h, with IC50 values of 0.093 micromol x L(-1) and 0.14 micromol x L(-1) respectively, which were superior to mycophenolic acid. The information obtained from the studies may be useful for further research on the immunosuppressive agents.
Collapse
Affiliation(s)
- Ya-Li Wang
- Key Laboratory of Structure-Based Drug Design & Discovery, Ministry of Education, Shengyang Pharmaceutical University, Shengyang 110016, China
| | - Qing-He Wang
- Key Laboratory of Structure-Based Drug Design & Discovery, Ministry of Education, Shengyang Pharmaceutical University, Shengyang 110016, China
| | - Hong-Guang Yang
- Key Laboratory of Structure-Based Drug Design & Discovery, Ministry of Education, Shengyang Pharmaceutical University, Shengyang 110016, China
| | - Bo-Jun Hao
- Key Laboratory of Structure-Based Drug Design & Discovery, Ministry of Education, Shengyang Pharmaceutical University, Shengyang 110016, China
| | - Guo-Dong Liang
- Key Laboratory of Structure-Based Drug Design & Discovery, Ministry of Education, Shengyang Pharmaceutical University, Shengyang 110016, China
| | - Chong-Guo Jiang
- Key Laboratory of Structure-Based Drug Design & Discovery, Ministry of Education, Shengyang Pharmaceutical University, Shengyang 110016, China
| | - Mao-Sheng Cheng
- Key Laboratory of Structure-Based Drug Design & Discovery, Ministry of Education, Shengyang Pharmaceutical University, Shengyang 110016, China
| |
Collapse
|
12
|
Yaseen S, Ovais S, Bashir R, Rathore P, Samim M, Singh S, Nair V, Javed K. Synthesis and biological evaluation of 4-arylphthalazones bearing benzenesulfonamide as anti-inflammatory and anti-cancer agents. Arch Pharm (Weinheim) 2013; 346:491-8. [PMID: 23670888 DOI: 10.1002/ardp.201300056] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/11/2013] [Revised: 03/21/2013] [Accepted: 03/28/2013] [Indexed: 11/09/2022]
Abstract
Nine 4-arylphthalazones bearing benzenesulfonamide (2a-i) were synthesized by the condensation of the appropriate 2-aroylbenzoic acid (1a-i) and 4-hydrazinobenzenesulfonamide in ethanol. The structures of these compounds were elucidated by elemental analysis, IR, ¹H NMR, ¹³C NMR, and MS spectroscopy. Two compounds, 2b and 2i, showed significant anti-inflammatory activity comparable to that of the standard drug celecoxib in the carrageenan-induced rat paw edema model. These compounds (2b and 2i) had selective inhibitory activity towards the COX-2 enzyme. Compound 2b had a better selectivity ratio (COX-1/COX-2) compared to that of celecoxib and can be used as a novel template for the design of selective COX-2 inhibitors. Compounds 2d and 2i were screened for their antiproliferative activity toward 60 human cancer cell lines by the National Cancer Institute (USA). The compounds 2d and 2i displayed mild activity toward the renal cancer cell line UO-31.
Collapse
Affiliation(s)
- Shafiya Yaseen
- Department of Chemistry, Faculty of Science, Jamia Hamdard (Hamdard University), New Delhi, India
| | | | | | | | | | | | | | | |
Collapse
|
13
|
Elagawany M, Ibrahim MA, Ali Ahmed HE, El-Etrawy AS, Ghiaty A, Abdel-Samii ZK, El-Feky SA, Bajorath J. Design, synthesis, and molecular modelling of pyridazinone and phthalazinone derivatives as protein kinases inhibitors. Bioorg Med Chem Lett 2013; 23:2007-13. [PMID: 23453843 DOI: 10.1016/j.bmcl.2013.02.027] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/21/2012] [Revised: 01/24/2013] [Accepted: 02/02/2013] [Indexed: 11/28/2022]
Abstract
The design and synthesis of pyridazinone and phthalazinone derivatives are described. Newly synthesized compounds were tested on a panel of four kinases in order to evaluate their activity and potential selectivity. In addition, the promising compounds were tested on four cancer cell lines to examine cytotoxic effects. The compounds inhibited DYRK1A and GSK3 with different activity. SAR analysis and docking calculations were carried out to aid in the interpretation of the results. Taken together, our findings suggest that pyridazinone and phthalazinone scaffolds are interesting starting points for design of potent GSK3 and DYRK1A inhibitors.
Collapse
Affiliation(s)
- Mohamed Elagawany
- Laboratoire d'innovation thérapeutique, UMR 7200, Faculté de Pharmacie, Université de Strasbourg, 74-route du Rhin, BP 60024, 67401 ILLKIRCH Cedex, France.
| | | | | | | | | | | | | | | |
Collapse
|
14
|
Derita M, del Olmo E, Barboza B, García-Cadenas AE, López-Pérez JL, Andújar S, Enriz D, Zacchino S, San Feliciano A. Synthesis, bioevaluation and structural study of substituted phthalazin-1(2H)-ones acting as antifungal agents. Molecules 2013; 18:3479-501. [PMID: 23507777 PMCID: PMC6270128 DOI: 10.3390/molecules18033479] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/14/2013] [Revised: 01/31/2013] [Accepted: 03/14/2013] [Indexed: 11/16/2022] Open
Abstract
Twenty-five polysubstituted phthalazinone derivatives were synthesized and tested for their antifungal activity against a panel of pathogenic and clinically important yeasts and filamentous fungi. Among them, the compound 4-(4-chlorobenzyl)-2-methylphthalazin-1(2H)-one (5) exhibited a remarkable antifungal activity against standardised strains of dermatophytes and Cryptococcus neoformans, as well as against some clinical isolates. A physicochemical study performed on compound 5 revealed its conformational and electronic characteristics, providing us with useful data for the future design of novel related antifungal analogues.
Collapse
Affiliation(s)
- Marcos Derita
- Pharmacognosy Department, Faculty of Biochemical and Pharmaceutical Sciences, National University of Rosario, Suipacha 531, 2000 Rosario, Argentine; E-Mail: (M.D.)
| | - Esther del Olmo
- Department of Pharmaceutical Chemistry, Faculty of Pharmacy, CIETUS-IBSAL, University of Salamanca, Campus Miguel de Unamuno, 37007 Salamanca, Spain; E-Mails: (B.B.); (A.E.G.-C.); (J.L.L.-P.); (A.S.F.)
- Authors to whom correspondence should be addressed; E-Mails: (E.D.O.); (S.Z.); Tel.: +34-923-294-528 (E.D.O.) Fax: +34-923-294-515 (E.D.O.)
| | - Bianca Barboza
- Department of Pharmaceutical Chemistry, Faculty of Pharmacy, CIETUS-IBSAL, University of Salamanca, Campus Miguel de Unamuno, 37007 Salamanca, Spain; E-Mails: (B.B.); (A.E.G.-C.); (J.L.L.-P.); (A.S.F.)
| | - Ana Esther García-Cadenas
- Department of Pharmaceutical Chemistry, Faculty of Pharmacy, CIETUS-IBSAL, University of Salamanca, Campus Miguel de Unamuno, 37007 Salamanca, Spain; E-Mails: (B.B.); (A.E.G.-C.); (J.L.L.-P.); (A.S.F.)
| | - José Luis López-Pérez
- Department of Pharmaceutical Chemistry, Faculty of Pharmacy, CIETUS-IBSAL, University of Salamanca, Campus Miguel de Unamuno, 37007 Salamanca, Spain; E-Mails: (B.B.); (A.E.G.-C.); (J.L.L.-P.); (A.S.F.)
| | - Sebastián Andújar
- Faculty of Chemistry, Biochemistry and Pharmacy, National University of San Luis (UNSL), Chacabuco 917, 5700 San Luis, Argentine; E-Mails: (S.A.); (D.E.)
- IMIBIO-CONICET, Universidad Nacional de San Luis, Chacabuco 915, 5700 San Luis, Argentina
| | - Daniel Enriz
- Faculty of Chemistry, Biochemistry and Pharmacy, National University of San Luis (UNSL), Chacabuco 917, 5700 San Luis, Argentine; E-Mails: (S.A.); (D.E.)
- IMIBIO-CONICET, Universidad Nacional de San Luis, Chacabuco 915, 5700 San Luis, Argentina
| | - Susana Zacchino
- Pharmacognosy Department, Faculty of Biochemical and Pharmaceutical Sciences, National University of Rosario, Suipacha 531, 2000 Rosario, Argentine; E-Mail: (M.D.)
- Authors to whom correspondence should be addressed; E-Mails: (E.D.O.); (S.Z.); Tel.: +34-923-294-528 (E.D.O.) Fax: +34-923-294-515 (E.D.O.)
| | - Arturo San Feliciano
- Department of Pharmaceutical Chemistry, Faculty of Pharmacy, CIETUS-IBSAL, University of Salamanca, Campus Miguel de Unamuno, 37007 Salamanca, Spain; E-Mails: (B.B.); (A.E.G.-C.); (J.L.L.-P.); (A.S.F.)
| |
Collapse
|
15
|
Procopiou PA, Browning C, Gore PM, Lynn SM, Richards SA, Slack RJ, Sollis SL. Synthesis and pharmacological investigation of azaphthalazinone human histamine H(1) receptor antagonists. Bioorg Med Chem 2012; 20:6097-108. [PMID: 22985961 DOI: 10.1016/j.bmc.2012.08.032] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/08/2012] [Revised: 08/14/2012] [Accepted: 08/16/2012] [Indexed: 01/15/2023]
Abstract
5-Aza, 6-aza, 7-aza and 8-aza-phthalazinone, and 5,8-diazaphthalazinone templates were synthesised by stereoselective routes starting from the appropriate pyridine/pyrazine dicarboxylic acids by activation with CDI, reaction with 4-chlorophenyl acetate ester enolate to give a β-ketoester, which was hydrolysed, and decarboxylated. The resulting ketone was condensed with hydrazine to form the azaphthalazinone core. The azaphthalazinone cores were alkylated with N-Boc-D-prolinol at N-2 by Mitsunobu reaction, de-protected, and then alkylated at the pyrrolidine nitrogen to provide the target H(1) receptor antagonists. All four mono-azaphthalazinone series had higher affinity (pK(i)) for the human H(1) receptor than azelastine, but were not as potent as the parent non-aza phthalazinone. The 5,8-diazaphthalazinone was equipotent with azelastine. The least potent series were the 7-azaphthalazinones, whereas the 5-azaphthalazinones were the most lipophilic. The more hydrophilic series were the 8-aza series. Replacement of the N-methyl substituent on the pyrrolidine with the n-butyl group caused an increase in potency (pA(2)) and a corresponding increase in lipophilicity. Introduction of a β-ether oxygen in the n-butyl analogues (2-methoxyethyl group) decreased the H(1) pA(2) slightly, and increased the selectivity against hERG. The duration of action in vitro was longer in the 6-azaphthalazinone series. The more potent and selective 6-azaphthalazinone core was used to append an H(3) receptor antagonist fragment, and to convert the series into the long acting single-ligand, dual H(1) H(3) receptor antagonist 44. The pharmacological profile of 44 was very similar to our intranasal clinical candidate 1.
Collapse
Affiliation(s)
- Panayiotis A Procopiou
- Medicinal Chemistry, GlaxoSmithKline Medicines Research Centre, Gunnels Wood Road, Stevenage, Hertfordshire SG1 2NY, United Kingdom.
| | | | | | | | | | | | | |
Collapse
|
16
|
Wang J, Bai X, Xu C, Wang Y, Lin W, Zou Y, Shi D. Ultrasound-promoted one-pot, three-component synthesis of spiro[indoline-3,1'-pyrazolo[1,2-b]phthalazine] derivatives. Molecules 2012; 17:8674-86. [PMID: 22825620 PMCID: PMC6268026 DOI: 10.3390/molecules17078674] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/08/2012] [Revised: 06/28/2012] [Accepted: 07/13/2012] [Indexed: 11/16/2022] Open
Abstract
A series of 3'-aminospiro[indoline-3,1'-pyrazolo[1,2-b]phthalazine]-2,5',10'-trione derivatives have been synthesized by a one-pot three-component reaction of isatin, malononitrile or ethyl cyanoacetate and phthalhydrazide catalyzed by piperidine under ultrasound irradiation. For comparison the reactions were carried out under both conventional and ultrasonic conditions. In general, improvement in rates and yields were observed when the reactions were carried out under sonication compared with classical conditions.
Collapse
Affiliation(s)
- Juxian Wang
- Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union, Medical College, Beijing 100050, China
| | - Xiaoguang Bai
- Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union, Medical College, Beijing 100050, China
| | - Changliang Xu
- Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union, Medical College, Beijing 100050, China
| | - Yucheng Wang
- Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union, Medical College, Beijing 100050, China
- Authors to whom correspondence should be addressed; (Y.W.); (D.S.); Tel./Fax: +86-10-6316-5263 (Y.W.)
| | - Wei Lin
- Key Laboratory of Organic Synthesis of Jiangsu Province, College of Chemistry, Chemical Engineering and Materials Science, Soochow University, Suzhou 215123, China
| | - Yi Zou
- Key Laboratory of Organic Synthesis of Jiangsu Province, College of Chemistry, Chemical Engineering and Materials Science, Soochow University, Suzhou 215123, China
| | - Daqing Shi
- Key Laboratory of Organic Synthesis of Jiangsu Province, College of Chemistry, Chemical Engineering and Materials Science, Soochow University, Suzhou 215123, China
- Authors to whom correspondence should be addressed; (Y.W.); (D.S.); Tel./Fax: +86-10-6316-5263 (Y.W.)
| |
Collapse
|
17
|
Zare L, Mahmoodi NO, Yahyazadeh A, Nikpassand M. Ultrasound-promoted regio and chemoselective synthesis of pyridazinones and phthalazinones catalyzed by ionic liquid [bmim]Br/AlCl3. Ultrason Sonochem 2012; 19:740-744. [PMID: 22306425 DOI: 10.1016/j.ultsonch.2011.11.008] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/15/2010] [Revised: 09/21/2011] [Accepted: 11/07/2011] [Indexed: 05/31/2023]
Abstract
The first ultrasound-promoted multicomponent synthesis of pyridazinones and phthalazinones from arenes, cyclic anhydrides and ArNHNH(2) in the presence of an efficient recyclable catalyst, [bmim]Br/AlCl(3), in high yield and short reaction time is reported.
Collapse
Affiliation(s)
- Leila Zare
- Department of Organic Chemistry, University of Guilan, P.O. Box 1914, Rasht, Iran
| | | | | | | |
Collapse
|
18
|
Shekouhy M, Hasaninejad A. Ultrasound-promoted catalyst-free one-pot four component synthesis of 2H-indazolo[2,1-b]phthalazine-triones in neutral ionic liquid 1-butyl-3-methylimidazolium bromide. Ultrason Sonochem 2012; 19:307-313. [PMID: 21868275 DOI: 10.1016/j.ultsonch.2011.07.011] [Citation(s) in RCA: 61] [Impact Index Per Article: 5.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/05/2011] [Revised: 07/14/2011] [Accepted: 07/25/2011] [Indexed: 05/31/2023]
Abstract
A catalyst-free one-pot four component methodology for the synthesis of 2H-indazolo[2,1-b]phthalazine-triones under ultrasonic irradiation at room temperature using 1-butyl-3-methylimidazolium bromide, [Bmim]Br, as a neutral reaction medium is described. A broad range of structurally diverse aldehydes (aromatic aldehydes bearing electron withdrawing and/or electron releasing groups as well as heteroaromatic aldehydes) were applied successfully, and corresponding products were obtained in good to excellent yields without any byproduct.
Collapse
Affiliation(s)
- Mohsen Shekouhy
- College of Chemistry, Islamic Azad University, Bandar Abbas Branch, Hormozgan, Iran.
| | | |
Collapse
|
19
|
Zhang S, Zhao Y, Liu Y, Chen D, Lan W, Zhao Q, Dong C, Xia L, Gong P. Synthesis and antitumor activities of novel 1,4-disubstituted phthalazine derivatives. Eur J Med Chem 2010; 45:3504-10. [PMID: 20537434 DOI: 10.1016/j.ejmech.2010.05.016] [Citation(s) in RCA: 31] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/26/2010] [Revised: 05/02/2010] [Accepted: 05/07/2010] [Indexed: 11/20/2022]
Affiliation(s)
- Shulan Zhang
- Key Laboratory of Original New Drug Design and Discovery of Ministry of Education, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenhe District, Shenyang, Liaoning 110016, PR China
| | | | | | | | | | | | | | | | | |
Collapse
|
20
|
Gouault N, Pinel B, Cupif JF, Depince A, Martin-Chouly CAE, Belleguic C, David M. Synthesis and Potential Anti-Inflammatory Activity of Some Tetrahydrophthalazinones. J Enzyme Inhib Med Chem 2008; 19:475-80. [PMID: 15662951 DOI: 10.1080/14756360412331280536] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022] Open
Abstract
A solid-phase route for the preparation of 4a,5,8,8a-tetrahydrophthalazinon-1-ones employing the Diels-Alder reaction has been developed. Some of the new compounds have been tested for inhibition of LPS-stimulated TNF-alpha production in human whole blood from patients with chronic obstructive pulmonary disease (COPD). This evaluation revealed two compounds 17 and 18 of interest, incorporating an arylpiperazine moiety, which were found to inhibit LPS-induced TNF-alpha release like the well known anti-inflammatory PDE4 inhibitors, rolipram and roflumilast.
Collapse
|
21
|
Ryu CK, Park RE, Ma MY, Nho JH. Synthesis and antifungal activity of 6-arylamino-phthalazine-5,8-diones and 6,7-bis(arylthio)-phthalazine-5,8-diones. Bioorg Med Chem Lett 2007; 17:2577-80. [PMID: 17320386 DOI: 10.1016/j.bmcl.2007.02.003] [Citation(s) in RCA: 110] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/22/2006] [Revised: 01/29/2007] [Accepted: 02/02/2007] [Indexed: 10/23/2022]
Abstract
6-Arylamino-phthalazine-5,8-diones and 6,7-bis(arylthio)-phthalazine-5,8-diones were synthesized and tested for in vitro antifungal activity against two pathogenic strains of fungi. Among those tested, many compounds showed good antifungal activity. The results suggest that phthalazine-5,8-diones would be potent antifungal agents.
Collapse
Affiliation(s)
- Chung-Kyu Ryu
- College of Pharmacy, Ewha Womans University, Seodaemun-ku, Seoul 120-750, Republic of Korea.
| | | | | | | |
Collapse
|
22
|
Zhang J, Pettersson HI, Huitema C, Niu C, Yin J, James MNG, Eltis LD, Vederas JC. Design, synthesis, and evaluation of inhibitors for severe acute respiratory syndrome 3C-like protease based on phthalhydrazide ketones or heteroaromatic esters. J Med Chem 2007; 50:1850-64. [PMID: 17381079 DOI: 10.1021/jm061425k] [Citation(s) in RCA: 61] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
The 3C-like protease (3CLpro), which controls the severe acute respiratory syndrome (SARS) coronavirus replication, has been identified as a potential target for drug design in the treatment of SARS. A series of tetrapeptide phthalhydrazide ketones, pyridinyl esters, and their analogs have been designed, synthesized, and evaluated as potential SARS 3CLpro inhibitors. Some pyridinyl esters are identified as very potent inhibitors, with IC50 values in the nanomolar range (50-65 nM). Electrospray mass spectrometry indicates a mechanism involving acylation of the active site cysteine thiol for this class of inhibitors.
Collapse
Affiliation(s)
- Jianmin Zhang
- Department of Chemistry, University of Alberta, Edmonton, Alberta, Canada T6G 2G2
| | | | | | | | | | | | | | | |
Collapse
|
23
|
Abstract
Novel potent derivatives of phthalazine are described as an adenosine triphosphate-competitive inhibitors of vascular endothelial growth factor receptors I and II. A number of compounds display vascular endothelial growth factor receptor II inhibitory activity reaching that of Vatalanib A (IC(50): < 50 nm) in an homogenous time-resolved fluorescence enzymatic assay.
Collapse
Affiliation(s)
- Alexander S Kiselyov
- Chemical Diversity, Inc., 11558 Sorrento Valley Road, Suite 5, San Diego, CA 92121, USA.
| | | | | | | |
Collapse
|
24
|
Li YX, Luo YP, Xi Z, Niu C, He YZ, Yang GF. Design and syntheses of novel phthalazin-1(2H)-one derivatives as acetohydroxyacid synthase inhibitors. J Agric Food Chem 2006; 54:9135-9. [PMID: 17117801 DOI: 10.1021/jf061976j] [Citation(s) in RCA: 43] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/12/2023]
Abstract
A series of 2-substituted-8-(4,6-dimethoxypyrimidin-2-yloxy)-4-methylphthalazin-1-one derivatives, 7a-7w, were designed via an ortho-substituent cyclization strategy to discover a new herbicidal lead structure. These compounds were synthesized by a seven-step route using 3-hydroxy-acetophenone as a starting material. Determination of the Ki values against wild-type A. thaliana acetohydroxyacid synthase (AHAS) (EC 4.1.3.18) indicated that some of the compounds displayed good enzyme inhibition activity comparable to that of KIH-6127. The further preliminary bioassay data on weeds showed that the synthesized compounds exhibited typical injury symptoms of AHAS-inhibiting herbicides, and some of them showed broad-spectrum and high herbicidal activities in postemergence treatments against Echinochloa crusgalli, Digitaria sanguinalis, Setaria viridis, Brassica juncea, Amaranthus retroflexus, and Chenopodium album at an application rate of 150 g ai/ha. To our knowledge, this is the first report of methylphthalazin-1-one derivatives as AHAS inhibitors.
Collapse
Affiliation(s)
- Yuan-Xiang Li
- Key Laboratory of Pesticide & Chemical Biology, Ministry of Education, College of Chemistry, Central China Normal University, Wuhan, Hubei 430079, People's Republic of China
| | | | | | | | | | | |
Collapse
|
25
|
Li J, Zhao YF, Yuan XY, Xu JX, Gong P. Synthesis and anticancer activities of novel 1,4-disubstituted phthalazines. Molecules 2006; 11:574-82. [PMID: 17971729 DOI: 10.3390/11070574] [Citation(s) in RCA: 119] [Impact Index Per Article: 6.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/25/2006] [Revised: 07/12/2006] [Accepted: 07/13/2006] [Indexed: 11/16/2022] Open
Abstract
A series of novel 1-anilino-4-(arylsulfanylmethyl)phthalazines were designed and synthesized. The structures of all the compounds were confirmed by IR, 1H-NMR, elemental analysis and MS. The analogues 1-(3-chloro-4-fluoroanilino)-4-(3,4- difluorophenylthio-methyl)phthalazine (12) and 1-(4-fluoro-3-trifluoromethylanilino)-4- (3,4-difluorophenyl-thiomethyl)phthalazine (13) showed higher activity than a cisplatin control when tested in vitro against two different cancer cell lines using the microculture tetrazolium method (MTT) method.
Collapse
Affiliation(s)
- Juan Li
- School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenhe District, 110016 Shenyang, Liaoning, P. R. China.
| | | | | | | | | |
Collapse
|
26
|
Abdelrazek FM, Michael FA, Mohamed AE. Synthesis and Molluscicidal Activity of Some 1,3,4-Triaryl-5-chloropyrazole, Pyrano[2,3-c]pyrazole, Pyrazolylphthalazine and Pyrano[2,3-d]thiazole Derivatives. Arch Pharm (Weinheim) 2006; 339:305-12. [PMID: 16649159 DOI: 10.1002/ardp.200500259] [Citation(s) in RCA: 29] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
2-(5-Chloro-1,3-diphenyl-1H-pyrazol-4-ylmethylene)-malononitrile 1a reacts with the arylidenes of malononitrile 2a-d to afford the triaryl-5-chloropyrazoles 3a-d, respectively. 1a reacts with the active methylene pyrazolinones 5a, b and 12a, b to afford different products 8, 9, 10, 11, and 14a, b--depending on the substitution in the pyrazole ring. Compound 1a reacts also with the pyridazinone derivative 15 to afford the phthalazinone 16, and with the thiazolinones 17a-c to afford the pyrano[2,3-d]thiazoles 20a-c, respectively. It reacts also with the malononitrile dimer 21a and with ethyl cyanoacetate dimer 21b to yield the pyrazolyl pyridines 22a, b, respectively. The synthesized compounds showed a moderate molluscicidal activity towards Biomphalaria alexandrina snails.
Collapse
Affiliation(s)
- Fathy M Abdelrazek
- Department of Chemistry, Faculty of Science, Cairo University, Giza, Egypt.
| | | | | |
Collapse
|
27
|
Duncton MAJ, Piatnitski EL, Katoch-Rouse R, Smith LM, Kiselyov AS, Milligan DL, Balagtas C, Wong WC, Kawakami J, Doody JF. Arylphthalazines. Part 2: 1-(Isoquinolin-5-yl)-4-arylamino phthalazines as potent inhibitors of VEGF receptors I and II. Bioorg Med Chem Lett 2006; 16:1579-81. [PMID: 16386418 DOI: 10.1016/j.bmcl.2005.12.045] [Citation(s) in RCA: 28] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/03/2005] [Revised: 12/08/2005] [Accepted: 12/08/2005] [Indexed: 11/24/2022]
Abstract
A novel class of 1-(isoquinolin-5-yl)-4-arylamino-phthalazines is described as inhibitors of vascular endothelial growth factor receptor II (VEGFR-2). Many compounds display VEGFR-2 inhibitory activity with an IC(50) as low as 0.017 microM in an HTRF enzymatic assay. The compounds also inhibit VEGFR-1, a related tyrosine kinase.
Collapse
Affiliation(s)
- Matthew A J Duncton
- Department of Chemistry, ImClone Systems, 710 Parkside Avenue, Suite 2, Brooklyn, NY 11226, USA.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
28
|
Cockcroft XL, Dillon KJ, Dixon L, Drzewiecki J, Kerrigan F, Loh VM, Martin NMB, Menear KA, Smith GCM. Phthalazinones 2: Optimisation and synthesis of novel potent inhibitors of poly(ADP-ribose)polymerase. Bioorg Med Chem Lett 2006; 16:1040-4. [PMID: 16290932 DOI: 10.1016/j.bmcl.2005.10.081] [Citation(s) in RCA: 68] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/05/2005] [Revised: 10/19/2005] [Accepted: 10/22/2005] [Indexed: 11/15/2022]
Abstract
We have previously described the discovery of poly(ADP-ribose)polymerase-1 (PARP-1) inhibitors based on a phthalazinone scaffold. Subsequent optimisation of inhibitory activity, metabolic stability and pharmacokinetic parameters has led to a novel series of meta-substituted 4-benzyl-2H-phthalazin-1-one PARP-1 inhibitors which retain low nM cellular activity and show good stability in vivo and efficacy in cell based models.
Collapse
Affiliation(s)
- Xiao-Ling Cockcroft
- KuDOS Pharmaceuticals Ltd 327 Cambridge Science Park, Milton Road, Cambridge, CB4 0WG, UK.
| | | | | | | | | | | | | | | | | |
Collapse
|
29
|
Kamal A, Reddy KL, Devaiah V, Shankaraiah N, Rao MV. Recent Advances in the Solid-Phase Combinatorial Synthetic Strategies for the Quinoxaline, Quinazoline and Benzimidazole Based Privileged Structures. Mini Rev Med Chem 2006; 6:71-89. [PMID: 16457633 DOI: 10.2174/138955706775197839] [Citation(s) in RCA: 56] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
Quinoxaline, quinazoline and benzimidazole based templates have been synthesized on solid-support employing different methodologies. This review enlightens academic and industrial examples of combinatorial synthesis for this type of heterocycles that appeared in the literature in the last decade. Hence, some of the important synthetic strategies for the generation of quinoxaline, quinazoline and benzimidazole based privileged structures, and the important biological activities for these heterocycles have been highlighted. Further, benzothiadiazinone, thioxoquinazolinone, cinnoline and indazole are also examined in this review.
Collapse
Affiliation(s)
- Ahmed Kamal
- Division of Organic Chemistry, Indian Institute of Chemical Technology, Hyderabad 500007, India.
| | | | | | | | | |
Collapse
|
30
|
Gritsan NP, Kim SN, Makarov AY, Chesnokov EN, Zibarev AV. Photochemistry of 1,3,2,4-benzodithiadiazines: formation and oxidation of 1,2,3-benzodithiazolyl radicals. Photochem Photobiol Sci 2006; 5:95-101. [PMID: 16395433 DOI: 10.1039/b510188c] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
Photolysis of 1,3,2,4-benzodithiadiazine and its derivatives in hydrocarbon solutions yields dinitrogen and stable 1,2,3-benzodithiazolyls (Herz radicals) whose interaction with dioxygen leads finally to O==S==N-substituted diphenyl disulfides via a self termination-like process with an effective second-order rate constant depending linearly on the concentration of dissolved O2.
Collapse
Affiliation(s)
- Nina P Gritsan
- Institute of Chemical Kinetics and Combustion, Siberian Branch of the Russian Academy of Sciences, 630090, Novosibirsk, Russia.
| | | | | | | | | |
Collapse
|
31
|
Piatnitski EL, Duncton MAJ, Kiselyov AS, Katoch-Rouse R, Sherman D, Milligan DL, Balagtas C, Wong WC, Kawakami J, Doody JF. Arylphthalazines: Identification of a new phthalazine chemotype as inhibitors of VEGFR kinase. Bioorg Med Chem Lett 2005; 15:4696-8. [PMID: 16143524 DOI: 10.1016/j.bmcl.2005.07.064] [Citation(s) in RCA: 40] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/25/2005] [Revised: 07/27/2005] [Accepted: 07/27/2005] [Indexed: 10/25/2022]
Abstract
A novel class of 4-arylamino-phthalazin-1-yl-benzamides is described as inhibitors of vascular endothelial growth factor receptor II (VEGFR-2). Several compounds display potent VEGFR-2 inhibitory activity with an IC50 as low as 0.078 microM in an HTRF enzymatic assay. These compounds are relatively selective against a small kinase panel.
Collapse
Affiliation(s)
- Evgueni L Piatnitski
- Department of Chemistry, ImClone Systems, 710 Parkside Avenue, Suite 2, Brooklyn, NY 11226, USA
| | | | | | | | | | | | | | | | | | | |
Collapse
|
32
|
Loh VM, Cockcroft XL, Dillon KJ, Dixon L, Drzewiecki J, Eversley PJ, Gomez S, Hoare J, Kerrigan F, Matthews ITW, Menear KA, Martin NMB, Newton RF, Paul J, Smith GCM, Vile J, Whittle AJ. Phthalazinones. Part 1: The design and synthesis of a novel series of potent inhibitors of poly(ADP-ribose)polymerase. Bioorg Med Chem Lett 2005; 15:2235-8. [PMID: 15837300 DOI: 10.1016/j.bmcl.2005.03.026] [Citation(s) in RCA: 76] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/20/2004] [Revised: 03/04/2005] [Accepted: 03/07/2005] [Indexed: 11/29/2022]
Abstract
Screening of the Maybridge compound collection identified 4-arylphthalazinones as micromolar inhibitors of PARP-1 catalytic activity. Subsequent optimisation of both inhibitory activity and metabolic stability led to a novel series of meta-substituted 4-benzyl-2H-phthalazin-1-ones with low nanomolar, cellular activity as PARP-1 inhibitors and promising metabolic stability in vitro.
Collapse
Affiliation(s)
- Vincent M Loh
- KuDOS Horsham Ltd, 26 Foundry Lane, Horsham, West Sussex RH13 5PX, UK.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
33
|
Demirayak S, Karaburun AC, Beis R. Some pyrrole substituted aryl pyridazinone and phthalazinone derivatives and their antihypertensive activities. Eur J Med Chem 2005; 39:1089-95. [PMID: 15571871 DOI: 10.1016/j.ejmech.2004.09.005] [Citation(s) in RCA: 141] [Impact Index Per Article: 7.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/14/2004] [Revised: 07/20/2004] [Accepted: 09/06/2004] [Indexed: 11/20/2022]
Abstract
In this work, some 2-nonsubstituted/2-methyl-/2-(2-acetyloxyethyl)-6-[4-(substituted pyrrol-1-yl)phenyl]-4,5-dihydro-3(2H)-pyridazinone, derivatives and 2-nonsubstituted/2-methyl- 4-[4-(substituted pyrrol-1-yl)phenyl]-1(2H)-phthalazinone derivatives were synthesised by reacting hexan-2,5-dion or 1-aryl-3-carbethoxypent-1,4-diones with corresponding 2-substituted/nonsubstituted 6-(4'-aminophenyl)-4,5-dihydro-3(2H)-pyridazinone or 2-substituted/nonsubstituted-4-(4'-aminophenyl)-(2H)-phthalazinone under Paal-Knorr pyrrole synthesis conditions. The antihypertensive activities of the compounds were examined both in vitro and in vivo. Some pyridazinone derivatives showed appreciable activity.
Collapse
Affiliation(s)
- Seref Demirayak
- Department of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Anadolu, 26470, Eskisehir, Turkey.
| | | | | |
Collapse
|
34
|
Russell MGN, Carling RW, Atack JR, Bromidge FA, Cook SM, Hunt P, Isted C, Lucas M, McKernan RM, Mitchinson A, Moore KW, Narquizian R, Macaulay AJ, Thomas D, Thompson SA, Wafford KA, Castro JL. Discovery of Functionally Selective 7,8,9,10-Tetrahydro-7,10-ethano-1,2,4-triazolo[3,4-a]phthalazines as GABAA Receptor Agonists at the α3 Subunit. J Med Chem 2005; 48:1367-83. [PMID: 15743180 DOI: 10.1021/jm040883v] [Citation(s) in RCA: 53] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
We have previously identified the 7,8,9,10-tetrahydro-7,10-ethano-1,2,4-triazolo[3,4-a]phthalazine (1) as a potent partial agonist for the alpha(3) receptor subtype with 5-fold selectivity in binding affinity over alpha(1). This paper describes a detailed investigation of the substituents on this core structure at both the 3- and 6-positions. Despite evaluating a wide range of groups, the maximum selectivity that could be achieved in terms of affinity for the alpha(3) subtype over the alpha(1) subtype was 12-fold (for 57). Although most analogues showed no selectivity in terms of efficacy, some did show partial agonism at alpha(1) and antagonism at alpha(3) (e.g., 25 and 75). However, two analogues tested (93 and 96), both with triazole substituents in the 6-position, showed significantly higher efficacy for the alpha(3) subtype over the alpha(1) subtype. This was the first indication that selectivity in efficacy in the required direction could be achieved in this series.
Collapse
Affiliation(s)
- Michael G N Russell
- Merck Sharp & Dohme Research Laboratories, Neuroscience Research Centre, Terlings Park, Eastwick Road, Harlow, Essex CM20 2QR, U.K.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
35
|
Sung Kim J, Lee HJ, Suh ME, Choo HYP, Lee SK, Park HJ, Kim C, Park SW, Lee CO. Synthesis and cytotoxicity of 1-substituted 2-methyl-1H-imidazo[4,5-g]phthalazine-4,9-dione derivatives. Bioorg Med Chem 2005; 12:3683-6. [PMID: 15186853 DOI: 10.1016/j.bmc.2004.04.014] [Citation(s) in RCA: 55] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/02/2004] [Revised: 04/14/2004] [Accepted: 04/14/2004] [Indexed: 11/19/2022]
Abstract
A series of 1-substituted 2-methyl-1H-imidazo[4,5-g]phthalazine-4,9-dione derivatives 8 was synthesized from 6,7-dichlorophthalazine-5,8-dione 5 and evaluated for in vitro cytotoxicity against several human tumor cell lines. Most of the tested compounds showed potential cytotoxic activity considerably higher than that of the reference compounds, ellipticine and doxorubicin.
Collapse
Affiliation(s)
- Jin Sung Kim
- College of Pharmacy, Ewha Womans University, Seoul 120-750, South Korea
| | | | | | | | | | | | | | | | | |
Collapse
|
36
|
Abstract
In this study, 6-[(4-arylidene-2-phenyl-5-oxoimidazolin-1-yl)phenyl]-4,5-dihydro-3(2H)-pyridazinone and 4-[(4-arylidene-2-phenyl-5-oxoimidazolin-1-yl)phenyl]-1(2H)-phthalazinone derivatives were synthesized by reacting 6-(4-aminophenyl)-4,5-dihydro-3(2H)-pyridazinone or 4-(4-aminophenyl)-1(2H)-phthalazinone compound with different 4-arylidene-2-phenyl-5(4H)-oxazolone derivatives. The vasodilator activities of the compounds were examined both in vitro and in vivo. Some pyridazinone derivatives showed appreciable activity.
Collapse
Affiliation(s)
- Seref Demirayak
- Dept. of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Anadolu, Eskisehir, Turkey.
| | | | | | | | | |
Collapse
|
37
|
Chang WF, Wen YS, Liu LK. 3,6-Bis(2-pyridyl)di-1,2,4-triazolo[3,4- a:4′,3′- c]phthalazine. Acta Crystallogr C 2004; 60:o665-7. [PMID: 15345850 DOI: 10.1107/s0108270104016737] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/27/2004] [Accepted: 07/08/2004] [Indexed: 11/10/2022] Open
Abstract
The title compound, C20H12N8, (I), has been prepared by the reaction of 1,4-dihydrazinophthalazine and pyridine-2-carboxaldehyde, followed by an oxidative cyclization by treatment with bromine. In the solid state, the molecules of (I) are discrete, comprising a fused and twisted four-ring system with an overall helical appearance. The distance between the two intramolecular pyridyl N atoms is 3.075 (2) A, this short contact distance suggesting a pi-pi interaction.
Collapse
Affiliation(s)
- Wen-Fu Chang
- Institute of Chemistry, Academia Sinica, Nankang, Taipei 115, Taiwan
| | | | | |
Collapse
|
38
|
Dogruer DS, Kupeli E, Yesilada E, Sahin MF. Synthesis of new 2-[1(2H)-phthalazinon-2-yl]acetamide and 3-[1(2H)-phthalazinon-2-yl]propanamide derivatives as antinociceptive and anti-inflammatory agents. Arch Pharm (Weinheim) 2004; 337:303-10. [PMID: 15188219 DOI: 10.1002/ardp.200200719] [Citation(s) in RCA: 49] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
As a consequence of our ongoing studies on heterocyclic compounds for new antinociceptive and anti-inflammatory agents bearing lactam functional group, new 2-[1(2H)-phthalazinon-2-yl]acetamide and 3-[1(2H)-phthalazinon-2-yl]propanamide derivatives have been synthesized. Among the compounds synthesized, compound (4e) was found the most active derivative in terms of antinociceptive and anti-inflammatory activities, without gastric lesions and bleeding at the given dose.
Collapse
Affiliation(s)
- Deniz S Dogruer
- Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Gazi University, Ankara, Turkey
| | | | | | | |
Collapse
|
39
|
Street LJ, Sternfeld F, Jelley RA, Reeve AJ, Carling RW, Moore KW, McKernan RM, Sohal B, Cook S, Pike A, Dawson GR, Bromidge FA, Wafford KA, Seabrook GR, Thompson SA, Marshall G, Pillai GV, Castro JL, Atack JR, MacLeod AM. Synthesis and biological evaluation of 3-heterocyclyl-7,8,9,10-tetrahydro-(7,10-ethano)-1,2,4-triazolo[3,4-a]phthalazines and analogues as subtype-selective inverse agonists for the GABA(A)alpha5 benzodiazepine binding site. J Med Chem 2004; 47:3642-57. [PMID: 15214791 DOI: 10.1021/jm0407613] [Citation(s) in RCA: 61] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
The identification of a novel series of 7,8,9,10-tetrahydro-(7,10-ethano)-1,2,4-triazolo[3,4-a]phthalazines as GABA(A)alpha5 inverse agonists, which have both binding and functional (efficacy) selectivity for the benzodiazepine binding site of alpha5- over alpha1-, alpha2-, and alpha3-containing GABA(A) receptor subtypes, is described. Binding selectivity was determined to a large part by the degree of planarity of the fused ring system whereas functional selectivity was dependent on the nature of the heterocycle at the 3-position of the triazolopyridazine ring. 3-Furan and 5-methylisoxazole were shown to be optimal for GABA(A)alpha5 functional selectvity. 3-(5-Methylisoxazol-3-yl)-6-(2-pyridyl)methyloxy-1,2,4-triazolo[3,4-a]phthalazine (43) was identified as a full inverse agonist at the GABA(A)alpha5 subtype with functional selectivity over the other GABA(A) receptor subtypes and good oral bioavailability.
Collapse
Affiliation(s)
- Leslie J Street
- Departments of Medicinal Chemistry, Biochemistry, and Pharmacology, Merck Sharp and Dohme Research Laboratories, Neuroscience Research Centre, Terlings Park, Eastwick Road, Harlow, Essex CM20 2QR, UK.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
40
|
Sternfeld F, Carling RW, Jelley RA, Ladduwahetty T, Merchant KJ, Moore KW, Reeve AJ, Street LJ, O'Connor D, Sohal B, Atack JR, Cook S, Seabrook G, Wafford K, Tattersall FD, Collinson N, Dawson GR, Castro JL, MacLeod AM. Selective, orally active gamma-aminobutyric acidA alpha5 receptor inverse agonists as cognition enhancers. J Med Chem 2004; 47:2176-9. [PMID: 15084116 DOI: 10.1021/jm031076j] [Citation(s) in RCA: 82] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
Nonselective inverse agonists at the gamma-aminobutyric acid(A) (GABA-A) benzodiazepine binding site have cognition-enhancing effects in animals but are anxiogenic and can precipitate convulsions. Herein, we describe novel GABA-A alpha5 subtype inverse agonists leading to the identification of 16 as an orally active, functionally selective compound that enhances cognition in animals without anxiogenic or convulsant effects. Compounds of this type may be useful in the symptomatic treatment of memory impairment associated with Alzheimer's disease and related dementias.
Collapse
Affiliation(s)
- Francine Sternfeld
- The Neuroscience Research Centre, Merck Sharp and Dohme Research Laboratories, Terlings Park, Eastwick Road, Harlow, Essex, CM20 2QR, UK.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
41
|
Lebsack AD, Gunzner J, Wang B, Pracitto R, Schaffhauser H, Santini A, Aiyar J, Bezverkov R, Munoz B, Liu W, Venkatraman S. Identification and synthesis of [1,2,4]triazolo[3,4-a]phthalazine derivatives as high-affinity ligands to the α2δ-1 subunit of voltage gated calcium channel. Bioorg Med Chem Lett 2004; 14:2463-7. [PMID: 15109633 DOI: 10.1016/j.bmcl.2004.03.008] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/03/2004] [Revised: 02/26/2004] [Accepted: 03/03/2004] [Indexed: 10/26/2022]
Abstract
We have identified and synthesized a series of [1,2,4]triazolo[3,4-a]phthalazine derivatives as high-affinity ligands to alpha 2 delta-1 subunit of voltage gated calcium channels. Structure-activity relationship studies directed toward improving the potency and physical properties of 2 lead to the discovery of 20 (IC(50)=15 nM) and (S)-22 (IC(50)=30 nM). A potent and selective radioligand, [(3)H]-(S)-22 was also synthesized to demonstrate that this ligand binds to the same site as gabapentin.
Collapse
Affiliation(s)
- Alec D Lebsack
- Department of Chemistry, Merck Research Laboratories, MRLSDB2, 3535 General Atomics Court, San Diego, CA 92121, USA.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
42
|
Lee HJ, Kim JS, Park SY, Suh ME, Kim HJ, Seo EK, Lee CO. Synthesis and cytotoxicity evaluation of 6,11-dihydro-pyridazo- and 6,11-dihydro-pyrido[2,3-b]phenazine-6,11-diones. Bioorg Med Chem 2004; 12:1623-8. [PMID: 15028255 DOI: 10.1016/j.bmc.2004.01.029] [Citation(s) in RCA: 31] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/07/2003] [Revised: 01/20/2004] [Accepted: 01/20/2004] [Indexed: 10/26/2022]
Abstract
The 6,11-dihydro-pyridazo[2,3-b]phenazine-6,11-dione and 6,11-dihydro-pyrido[2,3-b]phenazine-6,11-dione derivatives were synthesized from 6,7-dichloro-5,8-phthalazinedione and 6,7-dichloro-5,8-quinolinedione, respectively, producing a series of new anticancer drugs. The cytotoxic activities of the prepared compounds were evaluated by a SRB (Sulforhodamine B) assay against the following tumor cell lines: A459 (human lung), SK-OV-3 (human ovarian), SK-MEL-2 (human melanoma), XF498 (human CNS), and HCT 15 (human colon). Almost all the derivatives of the 6,11-dihydro-pyridazo[2[,3-b]phenazine-6,11-dione and 6,11-dihydro-pyrido[2,3-b]phenazine-6,11-dione, tetracyclic heteroquinone analogues with four or three nitrogen atoms, exhibited excellent cytotoxicity on almost all the human tumor cell lines tested. Specifically, 6,11-dihydro-pyridazo[2,3-b]phenazine-6,11-dione (4a) exhibited potent activity against all the tumor cell lines, and in particular, its cytotoxic effect against HCT 15 (ED(50)=0.004 microg/mL) was 25 times greater than that of doxorubicin (ED(50)=0.093 microg/mL).
Collapse
Affiliation(s)
- Hyun-Jung Lee
- Division of Medicinal Chemistry, College of Pharmacy, Ewha Woman's University, Seoul 120-750, South Korea
| | | | | | | | | | | | | |
Collapse
|
43
|
Carling RW, Moore KW, Street LJ, Wild D, Isted C, Leeson PD, Thomas S, O'Connor D, McKernan RM, Quirk K, Cook SM, Atack JR, Wafford KA, Thompson SA, Dawson GR, Ferris P, Castro JL. 3-Phenyl-6-(2-pyridyl)methyloxy-1,2,4-triazolo[3,4-a]phthalazines and Analogues: High-Affinity γ-Aminobutyric Acid-A Benzodiazepine Receptor Ligands with α2, α3, and α5-Subtype Binding Selectivity over α1. J Med Chem 2004; 47:1807-22. [PMID: 15027873 DOI: 10.1021/jm031020p] [Citation(s) in RCA: 117] [Impact Index Per Article: 5.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
Studies with our screening lead 5 and the literature compound 6 led to the identification of 6-benzyloxy-3-(4-methoxy)phenyl-1,2,4-triazolo[3,4-a]phthalazine 8 as a ligand with binding selectivity for the gamma-aminobutyric acid-A (GABA-A) alpha 3- and alpha 5-containing receptor subtypes over the GABA-A alpha 1 subtype (K(i): alpha 2 = 850 nM, alpha 3 = 170 nM, alpha 5 = 72 nM, alpha 1 = 1400 nM). Early optimization studies identified the close analogue 10 (K(i): alpha 2 = 16 nM, alpha 3 = 41 nM, alpha 5 = 38 nM, alpha 1 = 280 nM) as a suitable lead for further study. High-affinity ligands were identified by replacing the 6-benzyloxy group of compound 10 with 2-pyridylmethoxy (compound 29), but binding selectivity was not enhanced (K(i): alpha 2 = 1.7 nM, alpha 3 = 0.71 nM, alpha 5 = 0.33 nM, alpha 1 = 2.7 nM). Furthermore, on evaluation in xenopus oocytes,(22) 29 was discovered to be a weak to moderate inverse agonist at all four receptor subtypes (alpha 1, -7%; alpha 2, -5%; alpha 3, -16%; alpha 5, -5%). Replacement of the 3-phenyl group of 29 with alternatives led to reduced affinity, and smaller 3-substituents led to reduced efficacy. Methyl substitution of the benzo-fused ring of 29 at the 7-, 8-, and 10-positions resulted in increased efficacy although selectivity was abolished. Increased efficacy and retention of selectivity for alpha 3 over alpha 1 was achieved with the 7,8,9,10-tetrahydro-(7,10-ethano)-phthalazine 62. Compound 62 is currently one of the most binding selective GABA-A alpha 3-benzodiazepine-site partial agonists known, and although its selectivity is limited, its good pharmacokinetic profile in the rat (33% oral bioavailability after a 3 mg/kg dose, reaching a peak plasma concentration of 179 ng/mL; half-life of 1 h) made it a useful pharmacological tool to explore the effect of a GABA-A alpha 2/alpha 3 agonist in vivo.
Collapse
Affiliation(s)
- Robert W Carling
- Department of Medicinal Chemistry, The Neuroscience Research Centre, Merck Sharp and Dohme Research Laboratories, Terlings Park, Eastwick Road, Harlow, Essex CM20 2QR, UK.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
44
|
Martínez V, Burgos C, Alvarez-Builla J, Fernández G, Domingo A, García-Nieto R, Gago F, Manzanares I, Cuevas C, Vaquero JJ. Benzo[f]azino[2,1-a]phthalazinium Cations: Novel DNA Intercalating Chromophores with Antiproliferative Activity. J Med Chem 2004; 47:1136-48. [PMID: 14971893 DOI: 10.1021/jm0310434] [Citation(s) in RCA: 46] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
New azaquinolizinium-type cations have been obtained from isochromane. The synthesis was completed over seven steps and included as the key feature an intramolecular Westphal condensation. This first example of the intramolecular process allowed the preparation of benzo[f]pyrido[2,1-a]phthalazinium and benzo[f]quino[2,1-a]phthalazinium salts, which were evaluated as DNA intercalators, DNA topoisomerase I inhibitors, and antiproliferative compounds. Both cationic systems behave as DNA intercalators and exhibit antiproliferative activity. The pentacyclic benzo[f]quino[2,1-a]phthalazinium cations also have an inhibitory effect on the catalytic activity of DNA topoisomerase I, without trapping of cleavage complexes. Structural characterization using density functional theory indicates that the fused ring systems are slightly nonplanar, and additional molecular modeling studies suggest a preferred orientation for the intercalating chromophores within a typical CpG or TpG intercalation site.
Collapse
Affiliation(s)
- Valentín Martínez
- Departamento de Química Orgánica, Universidad de Alcalá, 28871-Alcalá de Henares, Madrid, Spain
| | | | | | | | | | | | | | | | | | | |
Collapse
|
45
|
Abstract
We report nineteen 4-aryl- and 4-arylalkyl-1-phthalazinamines (5-8) which we prepared and tested for antithrombotic properties. All compounds were assayed for their antiplatelet activity in the "Born test" with collagen as inducer of the aggregation. N-[4-(1H-1, 2, 4-triazol-1-yl)butyl]-4-phenyl-1-phthalazin-amine (7 c) was the most potent compound, having an IC(50) of 8 microM. When 5-HT (Serotonin) was used to start aggregation the N-(furan-2-yl-methyl)-4-phenyl-1-pthtalazinamine (8 a) had an IC(50) of 2 microM. In vivo potencies were highly significant. N-[5-(1H-1, 2, 4-triazol-1-yl)pentyl]-4-phenyl-1-phthalazinamine (7 d) inhibited thrombus formation by 12% (P < 0.002) in arterioles and 7% (P < 0.01) in venoles as tested with our laser thrombosis model. For compound 8 a we surprisingly found an antagonism to the 5HT(2A) receptor, which is most likely the mechanism of the inhibition of aggregation by this compound.
Collapse
Affiliation(s)
- Matthias Johnsen
- Institut für Pharmazie, Freie Universität Berlin, Berlin, Germany
| | | | | | | | | |
Collapse
|
46
|
Abstract
Coupling of the trimethylsilyl derivative of (2H)phthalazin-1-one with 1,2,3,4,6-penta-O-acetyl-alpha-D-glucopyranose and 1,2,3,4,6-penta-O-acetyl-alpha-D-galactopyranose in the presence of stannic chloride gave the respective glycosides, 2-(per-O-acetyl-D-glycosyloxy)phthalazines, which upon deacetylation gave the respective unprotected analogues. Under the same conditions 1,2,3,5-tetra-O-acetyl-beta-D-ribofuranose gave 1-(2,3,5-tri-O-acetyl-alpha-D-ribofuranosyloxy)phthalazine. Electrospray mass spectrometry aided the structural characterization of this series of 1-(D-glycosylyloxy)phthalazines. Low energy collisionally-induced dissociation tandem mass spectrometry of the protonated molecules confirmed the MS fragmentation routes and the structural identities of this novel series of glycosides.
Collapse
Affiliation(s)
- Abdellfattah Z Haikal
- Department of Chemistry, Faculty of Science, University of United Arab Emirates, PO Box 17551, Alain, United Arab Emirates
| | | | | |
Collapse
|
47
|
Drevs J. PTK/ZK (Novartis). IDrugs 2003; 6:787-94. [PMID: 12917775] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 03/04/2023]
Abstract
PTK/ZK, a VEGF receptor tyrosine kinase inhibitor, is under development by Novartis AG and Schering AG as an inhibitor of angiogenesis for the potential treatment of various cancers.
Collapse
Affiliation(s)
- Joachim Drevs
- Institute of Molecular Oncology, Department of Medical Oncology, Tumor Biology Center, Breisacher Strasse 117, 79106 Freiburg, Germany.
| |
Collapse
|
48
|
Rodríguez-Ciria M, Sanz AM, Yunta MJR, Gomez-Contreras F, Navarro P, Fernandez I, Pardo M, Cano C. Synthesis and cytotoxic activity of N,N-bis-(3-[N-(4-chlorobenzo[g]-phthalazin-1-yl)]aminopropyl)-N-methylamine: a new potential DNA bisintercalator. Bioorg Med Chem 2003; 11:2143-8. [PMID: 12713823 DOI: 10.1016/s0968-0896(03)00127-5] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
The synthesis of a new series of mono- and dinuclear 1-alkylamino-4-chlorobenzo[g]phthalazine derivatives 7-10 containing flexible polyaminic chains is reported. It has been achieved by the reaction of 1,4-dichlorobenzo[g]phthalazine with the corresponding polyamines. In vitro antitumoral activity against HT-29 human colon carcinoma cells was evaluated and showed best results for compound 10, in which two heteroaromatic units are linked by a N-methylsubstituted polyaminic chain. Molecular modelling of the complexes of 9 and 10 with DNA strongly suggests the possibility of bisintercalation, and also that the N-methyl group of 10 plays an important role in the formation of a specially stable DNA complex.
Collapse
Affiliation(s)
- Marinela Rodríguez-Ciria
- Departamento de Quimica Organica I, Facultad de Quimica, Universidad Complutense, 28040 Madrid, Spain
| | | | | | | | | | | | | | | |
Collapse
|
49
|
Van der Mey M, Bommelé KM, Boss H, Hatzelmann A, Van Slingerland M, Sterk GJ, Timmerman H. Synthesis and structure-activity relationships of cis-tetrahydrophthalazinone/pyridazinone hybrids: a novel series of potent dual PDE3/PDE4 inhibitory agents. J Med Chem 2003; 46:2008-16. [PMID: 12723963 DOI: 10.1021/jm030776l] [Citation(s) in RCA: 55] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
In this study, the synthesis and in vitro and in vivo pharmacological investigations of a new series of phthalazinone/pyridazinone hybrids with both PDE3 and PDE4 inhibitory activities are described. These compounds combine the pharmacophores of recently discovered 4a,5,8,8a-tetrahydro-2H-phthalazin-1-one-type inhibitors of PDE4 and the well-known 2H-pyridazin-3-one-type PDE3 inhibitors such as the tetrahydrobenzimidazoles. Most of the synthesized compounds are pharmacologically spoken PDE3/PDE4 hybrids. All hybrids show potent PDE4 inhibitory activity (pIC(50) = 7.0-8.7), whereas the pIC(50) values for inhibition of PDE3 vary from 5.4 to 7.5. In general, analogues with a 5-methyl-4,5-dihydropyridazinone moiety exhibit the highest PDE3 inhibitory activities. The highest in vivo antiinflammatory activity is displayed by phthalazinones 43 and 44 showing, at a dose of 30 micromol/kg po, 46% inhibition of arachidonic acid (AA) induced mouse ear edema. No correlation was found between the in vitro PDE3 and/or PDE4 inhibitory activity and the in vivo antiinflammatory capacity after oral dosing.
Collapse
Affiliation(s)
- Margaretha Van der Mey
- Leiden/Amsterdam Center for Drug Research, Division of Medicinal Chemistry, Department of Pharmacochemistry, Vrije Universiteit, De Boelelaan 1083, 1081 HV Amsterdam, The Netherlands.
| | | | | | | | | | | | | |
Collapse
|
50
|
Abstract
In the present study, a series of 1-substituted-4-hydroxyphthalazines were synthesized and characterized by IR, 1H-NMR and Elemental analysis. The compounds were assayed against seizures induced by maximal electroshock (MES) and pentylenetetrazole (scMet). Neurologic deficit was evaluated by the rotarod test. The decrease in the elevated motor activity by introceptive chemical stimuli (amphetamine antagonistic activity) was studied at the dose level of 25 and 50 mg kg(-1) and cardiac activity was also studied. All the compounds exhibited significant anticonvulsant activity. Compounds 4, 12, 13 and 17 were most active of the seriesagainst MES-induced seizures. Compounds 2, 4, 13 and 17 exhibited significant decrease in the elevated motor activity at the dose of 50 mg kg(-1). Remarkable sympathetic blocking activity was observed with 3, 5, 6, 7, 9 and 15 only.
Collapse
Affiliation(s)
- Ramaiya Sivakumar
- Department of Pharmaceutical Chemistry and Pharmacology, Vel's College of Pharmacy, Old Pallavaram, Chennai 600 117, India
| | | | | | | |
Collapse
|